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nervous system in a patient with human immunodeficiency 
virus: A case report
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ABSTRACT
Introduction: Central nervous system (CNS) vasculitis is rare, including in human 
immunodeficiency virus (HIV), occurring in less than 1% of patients. Systemic vasculitis affecting 
the CNS is termed secondary CNS vasculitis, whereas primary CNS vasculitis, referred to as 
primary angiitis of the CNS (PACNS) refers to an extremely rare disease specifically confined to 
the CNS. Only some cases of PACNS in HIV patients have been reported in literature. 
Case Report: We report a case of a 46-year-old female with HIV who developed probable primary 
CNS vasculitis, which was treated with intravenous cyclophosphamide and glucocorticoids 
for both induction and maintenance. A systematic literature review regarding PACNS and its 
therapeutic management is presented in this report. There were no clinical trials for PACNS. 
Based on the American Academy of Neurology (AAN) classes of evidence for therapeutic 
effectiveness, most data is of intermediate or weak strength. 
Conclusion: This case highlights diagnostic and clinical features of PACNS and provides 
an overview of the current literature regarding pharmacotherapy. Further case reports and 
additional studies are needed.
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ABSTRACT
Introduction: Central nervous system 
(CNS) vasculitis is rare, including in human 
immunodeficiency virus (HIV), occurring in less 
than 1% of patients. Systemic vasculitis affecting 
the CNS is termed secondary CNS vasculitis, 
whereas primary CNS vasculitis, referred to as 
primary angiitis of the CNS (PACNS) refers to 
an extremely rare disease specifically confined 
to the CNS. Only some cases of PACNS in HIV 
patients have been reported in literature. Case 
Report: We report a case of a 46-year-old female 
with HIV who developed probable primary CNS 
vasculitis, which was treated with intravenous 
cyclophosphamide and glucocorticoids for 
both induction and maintenance. A systematic 
literature review regarding PACNS and its 
therapeutic management is presented in this 
report. There were no clinical trials for PACNS. 
Based on the American Academy of Neurology 
(AAN) classes of evidence for therapeutic 
effectiveness, most data is of intermediate or 
weak strength. Conclusion: This case highlights 
diagnostic and clinical features of PACNS and 
provides an overview of the current literature 
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INTRODUCTION
Primary angiitis of the CNS (PACNS), also referred to 
as primary CNS vasculitis (PCNSV), CNS vasculitis, and 
previously, cerebral or primary granulomatous angiitis, 
is an extremely rare but serious disease with an incidence 
of 2.4 cases per one million person-years [1–3]. PACNS, 
unlike other vasculitides, is confined to the CNS. HIV is 
associated with various systemic vasculitides, from small 
to large vessel, immune-mediated to infectious. However, 
PACNS is less common than any systemic vasculitis 
in both the general population as well as in patients 
with HIV [4]. After an extensive literature review only 
a few case reports of PACNS in HIV patients have been 
identified [5, 6]. Further, in view of diagnostic advances 
and updated classification, it is uncertain if these cases 
represent true PACNS [7].
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PACNS remains a diagnostic challenge as presentation 
varies from patient to patient and can range from strokes 
to chronic headaches. It occurs with the same frequency 
in men and women with a median age of 50 years and 
may occur in both adult and pediatric patients [8, 9]. 
However, the presentation and treatment in pediatric 
patients differs from that of adults [2, 8]. Therefore, this 
review is limited to adult patients with PACNS. 
The disease is characterized by inflammatory 
infiltrates composed of lymphocytes, together with 
necrosis limited to the medium and small vessels of the 
CNS. The Calabrese diagnostic criteria were developed 
over 20 years ago, however, MRI scan and pathology 
are the best diagnostic tools as clinical findings are non-
specific and blood tests are usually normal [10]. Recently, 
subtypes of PACNS have been identified; however, 
classification remains a challenge [11]. Morbidity and 
mortality are associated with cerebral infarctions and 
involvement of large vessels. The prognosis has improved 
since 1983, when Cupps et al. reported success using a 
combination of cyclophosphamide and glucocorticoids 
[12].
Today, treatment includes glucocorticoids and 
cyclophosphamide, as it remains difficult to predict which 
patients would do well with glucocorticoid monotherapy 
[3, 12]. Cyclophosphamide has been shown to improve 
survival [12]. The optimal duration of treatment is 
unknown for this off-label use. Outcome is variable with 
some patients fully recovering and others experiencing 
permanent neurological damage. Toxicities associated 
with cyclophosphamide include urothelial toxicity such 
as cystitis, hematuria, bladder cancer, and infertility. 
Glucocorticoid toxicity includes bone loss, osteoporosis, 
diabetes mellitus, and Cushing ’s syndrome.
In patients intolerant to cyclophosphamide or those 
who respond poorly to the drug, rituximab has been 
used [2, 13]. Some patients receive weekly intramuscular 
methotrexate maintenance therapy. Other alternatives 
include azathioprine, chlorambucil, tocilizumab, 
cyclosporine, aspirin, tumor necrosis factors (infliximab 
and etanercept), and mycophenolate mofetil [1, 14–16].
We report a case of probable PACNS in a patient 
with HIV treated successfully with cyclophosphamide 
and pulse corticosteroids. Additionally, we conducted 
a systematic literature review for PACNS and evaluated 
the strength of the evidence using modified American 
Academy of Neurology (AAN) classes of evidence for 
therapeutic effectiveness criteria [17].
CASE REPORT 
A 46-year-old female was admitted for headache, 
vertigo, and an altered mental state. For several days 
prior to presentation, she developed increasing confusion 
and forgetfulness. She showed anterograde amnesia and 
was not oriented to day or time. Her past medical history 
included type 2 diabetes mellitus, HIV, hypertension, 
depression, and vertigo. Her home medications were 
metformin 500 mg twice daily, insulin glargine 10 units 
SQ nightly at bedtime, benazepril 20 mg once daily, 
amlodipine 10 mg once daily, escitalopram 10 mg once 
daily, atorvastatin 20 mg once daily, dolutegravir 50 mg 
once daily, lamivudine-abacavir 300 mg/600 mg once 
daily, and sulfamethoxazole-trimethoprim 800 mg/160 
mg once daily. She also had a tooth extraction and a 
cold several days prior to the onset of her presenting 
symptoms. Her social history was positive for former 
illicit substance abuse. In the emergency department, 
she received acetaminophen 650 mg and meclizine 25 
mg for symptom management. Her initial coagulation 
studies, complete blood count, and chemistries were 
unremarkable except for mild hyperglycemia (118 mg/
dL, N 74–106), hyperbilirubinemia (2.4 mg/dL, N 0.2–
1.3), and an ESR of 48 mm/hr (N 0–24). The patient’s 
CD4 count was 1026 cells/mm3, hemoglobin A1C was 
7.8, and vitamin B12 and TSH were within normal limits. 
At this time the patient’s weight was 93 kg. Her initial 
neurologic evaluation was non-focal apart from altered 
mentation. She was admitted while a broad infectious 
and inflammatory workup commenced.
A non-contrast computed tomography (CT) scan of the 
head revealed a right occipital hypodensity with minimal 
mass effect on the adjacent brain parenchyma and no 
evidence of midline shift, most consistent with subacute 
infarct, and was otherwise unremarkable appearing.
Subsequent brain magnetic resonance imaging 
(MRI) scan with and without contrast revealed acute 
infarcts in multiple vascular territories, including 
infarcts in the right middle cerebral artery distribution, 
left paramedian pons, bilateral occipital lobes, as well as 
punctate infarcts in the posterior left frontal lobe (Figures 
1 and 2). Vascular imaging revealed severe proximal 
basilar artery stenosis, bilateral distal vertebral artery 
stenosis, and moderate bilateral internal carotid artery 
cavernous stenosis. A lumbar puncture was performed 
and a cerebrospinal fluid (CSF) analysis was unrevealing 
apart from lymphocytosis. Though a broad infectious 
workup was negative, her clinical status worsened, and 
she was started on cyclophosphamide for presumed CNS 
vasculitis. Subsequent MRI scan revealed new infarcts 
in the inferior right cerebellum in the distribution of the 
right posterior inferior cerebellar artery, as well as in the 
splenium of the corpus callosum, expansion of infarcts 
in the right paramedian pons and corpus callosum, and 
hemorrhagic conversion of the right occipital infarct. 
A conventional angiogram was consistent with 
vasculitis, and even though a brain biopsy was 
performed, it did not capture a representative area 
of inflammation that was seen on MRI. While tissue 
diagnosis is considered the gold standard, repeat 
biopsy was not pursued, as the risks did not outweigh 
the benefits given the clinical context, high pretest 
probability, and her response to treatment. Therefore, 
she was diagnosed with probable PACNS based on her 
fulminant course with multiple successive strokes in the 
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setting of lymphocytic CSF pleocytosis, conventional 
angiogram consistent with vasculitis, and absence of 
systemic vasculitis. Furthermore, she was stabilized after 
prolonged course of high dose steroids with additional 
pulse dose cyclophosphamide. Additionally, her HIV was 
controlled, with a CD4 count of 1026 cells/mm3, and she 
was kept on daily pneumocystis jiroveci prophylaxis with 
sulfamethoxazole-trimethoprim.
At the time of submission of this report, the patient 
had received three cycles of cyclophosphamide therapy. 
During the first cycle the patient received intravenous 
cyclophosphamide 1000 mg after hydration with 0.9% 
NS, and premedication with ondansetron 16 mg IVPB for 
nausea. The patient was started on prednisone 80 mg once 
daily at the start of cyclophosphamide therapy, which was 
continued upon discharge. Approximately four weeks 
later, the patient was admitted again for the second cycle 
of the same regimen. An MRI scan during this admission 
showed stable infarcts compared to baseline. The patient 
received the same premedication and intravenous 
hydration as in cycle one. Approximately four weeks after 
the second cycle, the patient was admitted for cycle three, 
consisting of the same regimen as before. At this time she 
was deemed to be neurologically stable and responding 
well to treatment. 
DISCUSSION
Central nervous system vasculitis can be classified 
as primary or secondary [3, 18, 19]. It is primary 
when there is no other involvement than the CNS and 
secondary when it occurs with other inflammatory or 
systemic conditions such as connective tissue diseases, 
autoimmune or infectious diseases such as polyarteritis 
nodosa, systemic lupus erythematosus, varicella zoster, 
and HIV [9, 18]. The precise causes and pathogenesis of 
PACNS are unknown.
Our patient was HIV positive but had no evidence 
of systemic vasculitis or systemic symptoms such as 
fever, weight loss, or malaise. Furthermore, there 
was no alternative etiology to PACNS. HIV itself can 
cause vasculitis, though this occurs as a consequence 
of opportunistic infections such as cytomegalovirus, 
meningitis, and mycobacterium avium [4, 9]. The 
vasculitis is thought to be mainly the result of an 
immune response. A pathogenic mechanism in HIV may 
be interaction of T cell mediated cells, superantigens, 
adhesion molecules, immune complexes, cytokines, and 
growth factors [4, 20].
Secondary CNS vasculitis such as infections (e.g. 
neurosyphilis), systemic vasculitis, and connective tissue 
disease should be ruled out in cases of suspected PACNS. 
Our patient did not have clinical or laboratory evidence 
of such processes, e.g. the anemia, thrombocytopenia, 
elevated liver enzymes, and low complement typically 
associated with systemic vasculitis [21]. Infectious causes 
of vasculitis were ruled out prior to placing the patient on 
cyclophosphamide, which is immunosuppressive.
Diagnostic criteria for PACNS were suggested in 1987 
by Calabrese and Mallek [21]. The differential diagnosis 
is broad and includes reversible cerebral vasoconstriction 
syndromes and systemic vasculitis [10, 22]. Reversible 
vasoconstriction syndrome may be associated with 
medications, hypertension, eclampsia or the postpartum 
period, and is the most common mimicker of PACNS. 
Other mimickers are listed in Table 1 [3, 21, 22–26].
Our patient presented with cognitive impairment 
and headache, which constitute the two most common 
Figure 1: MRI brain diffusion imaging (DWI left, ADC on 
right) revealing diffusion-positive strokes in multiple vascular 
territories.
Figure 2: MRI brain (axial FLAIR slices) revealing multiple 
areas of hyperintensity.
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presenting symptoms, however, they are non-specific 
and made diagnosis difficult. Focal neurological deficits 
a common presenting symptom due to acute ischemic 
events, were absent on initial presentation. Subsequent 
cerebrovascular imaging was consistent with cerebral 
vasculitis. Clinical features of PACNS are listed in Table 2 
[3, 10, 24, 25, 27–29]. 
Our patient had involvement of the vertebral and 
basilar arteries, a feature commonly reported with CNS 
vasculitis [15]. Multiple ischemic infarctions visible on 
MRI, which occur in 53% of patients, and intracranial 
hemorrhages which occur in 9% of cases, were found 
in our patient as well [1, 3]. Hemorrhage is caused by 
vasculitis-induced blood vessel weakening or aneurysm 
formation [24]. Thus, our patient can be included in the 
most ominous subset of patients, i.e., rapidly progressive 
PACNS.
A literature search was performed to retrieve all 
publications describing medications used to treat 
PACNS. The search was conducted in PubMed (1966– 
March 2016), EMBASE (1980–2016), Ovid and the 
Cochrane Library, and Google Scholar using the search 
terms “primary angiitis”, “primary vasculitis”, “PACNS”, 
“PCNSV”, and “primary cerebral or granulomatous 
vasculitis”. No language or date restrictions were 
considered. The FDA website was utilized for identification 
and review of the latest prescribing information [30]. 
Included were randomized controlled trials, cohort 
and case control studies, professional guidelines or 
recommendations, case reports, case series, and studies 
conducted on small numbers of patients. Preclinical 
and chemical screening studies, review articles (other 
than Meta-analysis or systematic reviews), letters to the 
editor, editorials, and commentaries were excluded. For 
each article identified, a second search was conducted 
both in the databases above as well as by reviewing the 
bibliography to locate additional articles. We included all 
reports of patients more than or equal to 18-year-old.
To identify the strength of the evidence regarding 
treatment for PACNS and evaluate evidence quality, 
a modified AAN level of evidence classification for 
therapeutic intervention was employed [17] using a three-
tiered system (i.e., strong, intermediate, weak). Strong 
evidence involved prospective randomized controlled 
trials or prospective matched group cohort studies 
directly relevant or inclusion in a Guideline. Intermediate 
evidence involved conflicting data in randomized clinical 
trials or cohort studies, case-control studies, evidence in 
the form of small or pilot trials or case series, or consensus 
recommendation in the absence of relevant clinical trials 
and better evidence than case reports. Weak evidence 
involved isolated or anecdotal case reports, expert 
opinion or where strong or intermediate evidence failed 
to include dosages, relapse details, or patient outcomes. 
Excluded was secondary vasculitis use or narrative 
review articles or where the only available literature 
regarding the use pertained to pre-clinical studies. 
Table 1: PACNS- The Great Masquerader- Conditions Mimicking 
PACNS
Infections Associated With CNS Vasculitis
Viral (Human 
immunodeficiency virus, 
varicella-zoster, 
cytomegalovirus)
Mycoplasma pneumoniae
Hepatitis Borrelia burgdorferi
Bacterial endocarditis Mycobacterium 
tuberculosis
Acute bacterial meningitis Rickettsia spp. (Rocky 
Mountain spotted fever, 
typhus)
Bartonella spp. Fungal infections 
(aspergillosis, 
coccidiomycosis, 
candidiasis)
Subarachnoid cysticercosis Neurosyphilis
Systemic Vasculitides
Lymphoma (especially Hodgkin’s 
disease)
Kawasaki disease
Polyarteritis nodosa Giant cell arteritis
Henoch-Schonlein purpura Takayasu’s arteritis
Wegener’s granulomatosis Churg-Strauss 
syndrome
Antineutrophil cytoplasmic antibody-
associated vasculitis
Behçet disease
Hypocomplementemic urticarial 
vasculitis
Connective Tissue Diseases
Neuropsychiatric lupus Mixed connective tissue disease
Rheumatoid arthritis Dermatomyositis
Sjogren’s syndrome Storage diseases
Inflammatory bowel disease Systemic lupus erythromatosis
Sarcoidosis Cogan syndrome
Morphea or linear 
scleroderma
Miscellaneous
Drug-induced cerebral 
vasculitis—thiouracil, allopurinol, 
minocycline, penicillamine, 
carbamazepine, phenytoin, 
methotrexate, isotrentino, 
heroin, cyclosporine, 
sympathomimetics such as 
cocaine, ergotamine, ephedrine, 
amphetamine, oxymetazoline, 
phenylpropanolamine)
Graft versus host disease
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Moyamoya syndrome Sneddon syndrome
Reversible posterior 
leukoencephalopathy syndrome
MELAS (Mitochondrial 
encephalomyopathy, 
lactic acidosis, stroke)
Degos disease Amyloid angiopathy
Fabry’s disease Pseudoxanthoma 
elasticum
Lipohyalinosis Postpartum angiopathy
Atypical multiple sclerosis Optic neuritis
Call—Fleming syndrome CADASIL
Migrainous vasospasm Susac syndrome
Whipple’s disease CNS malignancy-related 
angiitis
Rasmussen encephalitis Hodgkin’s and non-
Hodgkin’s lymphoma
Radiation vasculopathy Intracranial dissection
Fibromuscular dysplasia N-methyl-o-aspartate 
receptor-mediated 
encephalitis
Table 2: Clinical and Diagnostic Characteristics of PACNS
Signs & Symptoms, Lab 
and Imaging Findings
Percentage Our Patient
Headache 63 +
Cognitive Impairment 50 +
Hemiparesis 44 -
Stroke 40 +
Aphasia 28 -
Transient ischemic attacks 28 -
Ataxia 19 -
Seizures 16 -
Dysarthria 15 -
Blurred or decreased visual 
acuity
11 -
Intracranial hemorrhage <10% +
Amnesic syndrome <10% +
Lymphomonocytic pleocytosis >90% +
Brain biopsy evidence 75% +
Mass lesions 15% -
Spinal cord involvement 5% -
Elevated ESR <25% +
Abnormal brain CT 50-60% +
Abnormal MRI 75% +
Table 3: Published Clinical Research of PACNS in Adults 
Drug Results Strength of Evidence Reference
N = 163 patients
G alone- IV M 1 g (3–17 pulses, median 5), 
then P 60 mg/day (median) for 0.4–107 mo 
(median 9 mo)
N Therapy
72 P + C
2  C
51 C PO 150 mg/day (1–33 mo)
23 C IV 1000 mg/mo (1–17 mo)
Azathioprine 100 mg/day (range 100–150 
mg/day) for 0.4–76 mo (median 11 mo) + P 
(6 patients)
Mycophenolate 2,000 mg/day (median) + P 
(3 patients)
Rituximab 2 injections (1 patient)
Favorable response 85% P alone; 
80% C + P
C + P; increased mortality rate
27% of patients relapsed
Relapse less frequent in patients 
treated with C + P versus P alone 
(OR 2.9)
Higher disability scores and poor 
response to treatment associated 
with increasing age at time of 
diagnosis (OR 1.44), cerebral 
infarctions (OR 3.74), large vessel 
involvement (OR 6.14)
-Intermediate evidence
- Cohort study 
(retrospective)
(mostly same patients 
as cohort below- study 
extension)
Salvarani 2015
N = 101 patients (over 21 years old period)
97 G
 -25- 1 g M 
 -72- 60 mg P daily
49- I
 -46 C PO 150 mg/day or IV 1 g/m2 
-3 azathioprine
Favorable response 81%- G alone
85% - G + I
Relapses occurred in 25%
-Intermediate evidence 
-Retrospective chart review
(could not conclude if 
necessary as group may 
have initially had more 
severe disease)
Salvarani 2007
International Journal of Case Reports and Images, Vol. 7 No. 10, October 2016. ISSN – [0976-3198]
Int J Case Rep Images 2016;7(10):644–652.  
www.ijcasereportsandimages.com
Rumore et al. 649
Most of the medications have only intermediate or 
weak evidence consisting of several small retrospective 
cohort studies and case reports (Table 3). The vast 
majority of literature pertains to systemic or secondary 
vasculitis with PACNS treatment recommendations 
derived from systemic vasculitis. No clinical trials in 
PACNS have been conducted. There is one cohort of 101 
patients and a second cohort that extends the follow-up 
and includes some additional patients (N=163) [1, 2]. 
These cohorts constitute intermediate evidence. All other 
literature retrieved regarding PACNS pharmacotherapy 
pertains to weak evidence.
Cyclophosphamide and glucocorticoids remain 
the standard of care. Cytotoxic agents have been used 
for CNS vasculitis for decades based on therapeutic 
protocols in systemic vasculitides, anecdotal reports 
and cohort studies with favorable results [12]. The use 
of cyclophosphamide was first described in 1978 for use 
in secondary vasculitis [31]. The mechanism appears 
to be autoantibody suppression. However, no clinical 
trials have been conducted and it is unknown whether 
cyclophosphamide is the most effective and least toxic 
cytotoxic agent. 
N= 52
- G (all but 1)- 7 as monotherapy (M for 3 
pulses 250–1000 mg, then P 1 mg/kg for 23 
mo
- 44 (85%) C 
(Pulse IV 0.6–0.7 g/m2 Q2–4 wks for 3 
pulses, then monthly for up to 12 pulses)
- 43 C+ G; 1 C alone
- Rituximab- 1 pt 375 mg/m2 weekly for 4 
infusions (for C refractory disease)
- Azathioprine- after C induction- 22 pts; 2 
mg/kg/day
-Methotrexate- 1 pt after induction
-Mycophenolate- 1pt after induction 
Favorable response 32/49 pts (65)
Relapse 13/49 (27%)
Death 3 (6%)
Rituximab effective for C 
refractory disease 
Patients receiving methotrexate or 
mycophenolate remained free of 
disease
Neurological damage persisted for 
82% of pts
Intermediate evidence
Cohort study
De Boysson 2014
M + C IV; 12 mo therapy
(no dosages provided)
Initial response to M followed by 
relapse at 3 weeks
Weak evidence
Case report
Rosenberg 2013
C IV + M (twice only-patient lost to follow-
up)
(dosages not provided)
Beneficial effect; no relapse at 2 
mo
Weak evidence
Case report
Bajij 2015
N=4; C + G Weak evidence
Case reports (4)
Cupps 1983
Rituximab (2 IV doses of 1 g 2 weeks apart) 
+ P 
(60 mg/day);
P continued for 8 mo- lowered to 20 mg/day;
maintenance therapy with methotrexate IM 
15 mg weekly for 5 mo + P 10 mg/day
No relapses at 13 mo
Methotrexate discontinued 
because of nausea and vomiting
Weak evidence
Case report
Salvarani 2014
TNF blockers- patients resistant to G + C
Infliximab 5 mg/kg single infusion
Etanercept 50 mg/week (for 20 mo); then 25 
mg once weekly (for 8 mo)
Rapid/effective improvement
Etanercept arrested relapse
No relapses at 34 and 60 mo
Weak evidence
Case reports (2)
Salvarani 2008
N= 15
No dosages reported.
8 patients on G, 2 patients also on C (others 
not reported)
1 patient on C+G improved after 
4 mo
1 patient on C+G died after 2 
weeks
5 improved; 3 with residual effects 
such as cortical blindness and 
confusion
Weak evidence
Case series
Lie 1992
C = cyclophosphamide
P= prednisone PO
M= methylprednisolone IV
G= glucocorticoids
I= immunosuppressants
Table 3: (Continued)
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There is controversy regarding whether to 
administer glucocorticoids as monotherapy or to add 
cyclophosphamide. In 163 patients with PACNS, a 
favorable response was observed in 80% of patients 
treated with prednisone and cyclophosphamide versus 
85% in patients treated with prednisone alone [2]. 
Prednisone alone was associated with more frequent 
relapses but relapses were not associated with rapid 
therapy withdrawal. It was noted that cerebral infarcts 
were associated with poor treatment responses. 
Predominant involvement of medium-sized vessels, as in 
our patient, may be less likely to respond to glucocorticoid 
monotherapy [25]. In addition to the presence of cerebral 
infarcts, large vessel involvement, focal neurological 
deficits and cognitive impairment are associated with 
increased mortality [1].
Prednisone should be initiated as soon as the diagnosis 
of PACNS is made at a single or divided dose of 1 mg/
kg/day orally. If the patient does not respond promptly, 
cyclophosphamide should be added. In life-threatening 
or severe/progressive cases and/or for disease flares, 
pulse parenteral methylprednisolone at 1 g for three days 
may be used but no evidence exists this is more effective 
than oral prednisone [3]. 
In addition to controversy over whether to add C, 
controversy also exists as to whether cyclophosphamide 
should be given as continuous oral therapy or intravenous 
pulse therapy and no trials have been conducted to answer 
this question. The goal of pulse therapy is to minimize 
cyclophosphamide exposure. In systemic vasculitis trials, 
intravenous cyclophosphamide was as effective and 
produced less leucopenia than oral cyclophosphamide 
in inducing remission [31, 32]. Relapse rates were not 
reported in either study [31, 32]. In another study, a 
higher relapse rate was observed with IV pulse use and 
adverse effects were more frequent with continuous oral 
cyclophosphamide [33]. However, that study investigated 
relatively short courses of treatment. There is some 
evidence that prolonged treatment with low-dose pulse 
cyclophosphamide for 18–24 months may reduce the rate 
of relapse [34]. Again, all these studies are in systemic 
vasculitis, not PACNS.
The pulse dose is monthly infusions of 15 mg/kg or 
500 to 1000 mg/m2 [24, 35]. The median oral dose of 
cyclophosphamide has been reported to be 150 mg/day 
with a range of 75–150 mg/day for a median duration 
of seven months with a range of 1–33 months [2]. An 
oral dosage of 2 mg/kg/day is frequently used. While 
the results of those trials are inconclusive, in other 
vasculitides, oral cyclophosphamide was successful when 
given for 3–6 months. Dosages should be adjusted for age 
and renal dysfunction [3].
Cyclophosphamide may result in life-threatening 
infections, cancer (particularly of the bladder or secondary 
lymphomas), hemorrhagic cystitis, and infertility. 
Bladder toxicity and myelodysplastic syndrome greatly 
increase with cumulative doses > 30 g [35]. Carcinoma 
of the renal pelvis was reported in a patient receiving 
long-term cyclophosphamide for cerebral vasculitis 
[36]. Immunosuppression from cyclophosphamide can 
result in serious, sometimes fatal infections and the 
degree of neutropenia correlates with reduced resistance 
to infections. Patients should receive pneumocystis 
prophylaxis with oral sulfamethoxazole/trimethoprim. 
Other supportive therapy includes antiemetics and 
normal saline hydration. While plasmapheresis is 
ineffective, intravenous immunoglobulin (IVIG) has been 
successful in some refractory patients [37].
While glucocorticoids remain the standard of care for 
remission, in patients unable to take cyclophosphamide, 
rituximab at a dose of 1 gm for two doses administered two 
weeks apart has been used. A double blind randomized 
trial in systemic vasculitis comparing rituximab to 
cyclophosphamide, found rituximab non-inferior to 
cyclophosphamide for remission induction and more 
effective for inducing remission of relapsing disease (67% 
versus 42%, p=0.01) [38]. 
After induction, many advocate switching to a low 
risk immunosuppressant to minimize cyclophosphamide 
exposure [3, 24, 29, 39]. The induction-maintenance 
strategy has been used in secondary vasculitis using 
azathioprine at 1–2 mg/kg/day  [40]. In a recent study, 
azathioprine was used in 25% of patients for maintenance 
therapy, following cyclophosphamide induction. 
However, in PACNS a treatment course for 12–18 
months, preferably 18, is used in most patients assuming 
relapses do not mandate prolonged therapy [3, 21]. 
Some continue maintenance therapy for 2–3 years [22]. 
Other agents include methotrexate at 20–25 mg/week, 
or mycophenolate mofetil at 1–2 g/day once remission 
has been obtained [3]. Comparison of methotrexate and 
azathioprine in patients with systemic vasculitis have 
not shown either to be superior, however, methotrexate 
does not penetrate the CNS well [29]. Methotrexate 
dosage should be reduced in patients with severe renal 
impairment [41].
In treatment-resistant cases, tumor necrosis factor α 
blockers (e.g. infliximab 5 mg/kg or etanercept 50 mg/
week) and mycophenolate mofetil (2 g/day) have been 
used. A relapse rate of approximately 25% may occur with 
serial MRI scan or MRA follow-up at 4th–6th week and at 
3rd–4th month intervals thereafter [3, 16, 25].
CONCLUSION
Primary angiitis of the central nervous system is a 
rare but serious disease that presents both diagnostic and 
therapeutic challenges. Favorable neurological outcome 
is a realistic goal. Knowledge regarding the epidemiology, 
pathogenesis, diagnosis and management continues 
to evolve. Optimal management remains uncertain. 
Pulse cyclophosphamide treatment and identification of 
patients to initially receive immunosuppressant therapy 
and alternatives require further investigation. 
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